论文部分内容阅读
为评价RPHA筛选的献血员,对输血后肝炎和HBV感染的预防效果,对224名献血员和204例受血者,于输血后进行丁6—7个月随访。将输血前后标本经同批RIA试剂检测HBV感染指征。受、献血前HBV感染率,在献血员和受血者中分别为62.9%和65.7%。RPHA筛选后的献血员,用RIA检测HBSAg阳性率仍有2.2%阳性。输血后肝炎发病率为1.5%(3/240),病原分型为非甲非乙查肝炎。在HBV易感者中,HBV感染率为14.3%(10/70)。两例HBSAg阳转,其中1例来自仅HBV—DNA阳性献血员。另1例来自单独抗—HBC和BBV—DNA阳性献血员。上述结果提示:1、为预防输血后乙型肝炎,用RpHA筛选献血员是不够的。2、输入抗—HBS和离滴度抗—HBC双阳性血液并不安全,特别是单独抗—HBC阳往者。3、输血4例临床型肝炎,1例为误输入乙型旰炎病毒所致,另3例是由NANB肝炎病毒所引起,应引起重视。
To evaluate the preventive effect of RPHA-selected blood donors on post-transfusion hepatitis and HBV infection, 224 blood donors and 204 recipients were enrolled and followed up for 6-7 months after transfusion. Before and after transfusion of blood samples by the same batch of RIA reagents to detect HBV infection indications. The pre-donation HBV infection rates were 62.9% and 65.7% for blood donors and recipients, respectively. Blood donors after RPHA screening still had 2.2% positive HbsAg positive rate by RIA. The incidence of post-transfusion hepatitis was 1.5% (3/240), the pathogen was classified as non-A, non-B hepatitis. In HBV susceptible, the HBV infection rate was 14.3% (10/70). Two cases of HBSAg yangzhuan, including one case from only HBV-DNA positive blood donors. The other 1 case was from anti-HBC and BBV-DNA positive blood donors alone. The above results suggest that: 1, in order to prevent post-transfusion hepatitis B, using RpHA screening blood donors is not enough. 2, the input of anti-HBS and anti-double titer anti-HBC blood is not safe, especially anti-HBC anti-Yang alone. 3, transfusion of 4 cases of clinical hepatitis, 1 case of false input due to hepatitis B virus, the other 3 cases caused by the NANB hepatitis virus, should pay attention.